Alexion regulatory update

The Oklahoma Medical Research Foundation received notice of allowance for a U.S. patent covering a class of compounds that inhibit the complement mediated inflammatory response. ALXN has an exclusive license to the patent. The allowed claims relate to both the commercial uses and compositions of a broad class of monoclonal antibodies that bind to complement component CD5. ...